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Abstract
Background: One of the most difficult areas in the fight against HIV/AIDS is reaching out to youth aged 13 to 24 years. The
proportion of youth living with HIV/AIDS on antiretroviral therapy (ART) and who are virally undetectable is low, highlighting
significant challenges for reaching the Joint United Nations Program on HIV targets.
Objective: This study aimed to assess the feasibility of obtaining key clinical indicators and monitoring treatment, viral
suppression, and retention components of the youth HIV treatment cascade in Adolescent Trials Network for HIV/AIDS
Interventions clinics using electronic health record (EHR) downloads and to provide baseline characteristics for the study
participants.
Methods: EHR data were systematically obtained from multiple clinical sites and used to meaningfully capture clinical
characteristics, initiation of antiretrovirals, and retention in care, which are part of the Centers for Disease Control and Prevention’s
4 continuum of care measures. In addition, this study used standard cost values attached to Current Procedural Terminology codes
to estimate the cost per visit.
Results: Only 2 of the 4 Centers for Disease Control and Prevention treatment cascade measures were assessed using routine
EHR data. EHR data are not adequate for monitoring HIV testing or linkage to care because denominator data are not available.
However, the data work well for measuring ART initiation and adequately for retention in care. The sites were broadly able to
provide information for the required data. However, in most cases, these data are insufficient for identifying patterns of missed
appointments because such misses are not captured in the EHR system. Sites with good access to data management resources
can operate more efficiently for cascade monitoring study purposes.
Conclusions: Data other than EHRs are needed to measure HIV testing and linkage to youth care. EHR data are useful for
measuring ART initiation and work moderately well for measuring retention in care. Site data management resources should be
part of the selection process when looking for site partners for clinical studies that plan to use EHR data. Study planners should
determine the feasibility of additional funding for organizations in need of additional information technology or data management
resources.
(JMIR Form Res 2022;6(4):e25483) doi: 10.2196/25483
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Introduction
Background
We have made substantial progress in preventing HIV infection
in the United States during the past decade, and the federal
government has recently released a national strategic plan to
end the HIV epidemic in the United States by 2030 [1].
However, one of the most difficult areas in the fight against the
HIV and AIDS epidemics is reaching youth. In the United
States, in 2016, approximately 21% of the 39,782 new HIV
diagnoses occurred among youth aged 13 to 24 years [2]. We
will not be able to end the HIV epidemic in the United States
unless we reach this age group. However, preventing new
HIV-positive diagnoses will require a 2-pronged attack, because
prevention must reach youth at risk of acquiring HIV and
treatment must reach those already living with HIV. The latter
is an often-neglected group [3]; however, we cannot conquer
the HIV epidemic in the United States without solving the youth
treatment cascade (ie, HIV testing and diagnosis, linkage to
care, and viral suppression) problem.
National-level strategies specify goals related to early HIV
diagnosis and effective care. The Centers for Disease Control
and Prevention (CDC) HIV care continuum identifies a dynamic
series of steps from the time a person receives a diagnosis of
HIV through the successful treatment of their infection with
HIV medications [4]. The HIV care continuum consists of
several steps that are required to achieve viral suppression.
Specifically, CDC tracks the following: (1) diagnosed—receives
a diagnosis of HIV, (2) linked to care—visited an HIV health
care provider within 1 month after learning they were HIV
positive, (3) received or were retained in care—received medical
care for HIV infection, and (4) viral suppression—their HIV
viral load (VL) was at a very low level. Although the HIV care
continuum is often presented as a static framework, individuals
who are HIV positive often exit and re-enter the continuum at
varying steps [5]. Although relatively straightforward
conceptually, programmatic implementation to systematically
monitor the HIV treatment cascade is quite challenging [6].
Despite the fact that studies have used study coordinator data
entry of cascade variables for consented participants [7], this
does not adequately reflect the range of youth at Adolescent
Trials Network for HIV/AIDS Interventions (ATN) clinics who
may not consent to such trials. To date, no studies have been
published on multisite youth cascade variables using electronic
health records (EHRs). To that end, Scale It Up (SIU), a
collaborative program (U19) within the ATN, aims to bring to
practice evidence-based self-management interventions via
hybrid implementation trials to positively impact the youth HIV
prevention and care cascades.

Objectives
The Cascade Monitoring (CM) protocol (ATN Protocol 154)
was designed to monitor the cascade within the ATN using EHR
and provide longitudinal effectiveness outcomes and cost
estimates [8]. The first goal of ATN 154 and the purpose of this
report are to assess the feasibility of assessing the youth HIV
treatment cascade [9] among those linked to care within the
ATN using EHR downloads. To this end, this study aims to
https://formative.jmir.org/2022/4/e25483
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assess the feasibility of obtaining key clinical indicators and
monitoring treatment, viral suppression, and retention
components of the youth HIV treatment cascade in ATN clinics
using EHR downloads. In addition, this study will use the first
data submissions from 10 study sites to estimate the cost per
visit and provide baseline study participant characteristics.

Methods
Ethics Approval
In compliance with ethical standards, the SIU CM study (ATN
154) was approved by an expedited review process by the single
institutional review board of Florida State University (approval
IRB00000446). All the procedures performed in this study were
in accordance with the ethical standards of the institutional
review board.

Study Sites
Limited EHR data were collected retrospectively, from 10
clinical sites, also known as subject recruitment venues,
participating in SIU: (1) Johns Hopkins University, Baltimore,
Maryland; (2) University of Alabama at Birmingham,
Birmingham, Alabama; (3) SUNY Downstate Medical Center,
Brooklyn, New York; (4) Children’s Hospital Los Angeles, Los
Angeles, California; (5) St Jude Children’s Research Hospital,
Memphis, Tennessee; (6) University of Miami, Miami, Florida;
(7) Children’s Hospital of Philadelphia, Philadelphia,
Pennsylvania; (8) University of California San Diego, San
Diego, California; (9) University of South Florida, Tampa,
Florida; and (10) Children’s National Health System,
Washington, District of Columbia.
The first data extract requested treatment visits in the full year
of 2016 and associated care data for all youth living with
HIV/AIDS, aged 15 to 24 years, treated at sites. Subsequently,
1-year data EHR extracts were received from sites annually,
with the final year of data uploaded in 2022 for the full year of
2021. Data were requested for a set of variables that were
considered invariant for the year 2016 (demographics) and for
variables where multiple annual values should be captured to
measure the treatment cascade changes. The variables requested
included demographics (age, sex, race, and ethnicity), height,
weight, International Statistical Classification of Diseases and
Related Health Problems–10th Revision (ICD-10) codes, and
Current Procedural Terminology (CPT) codes. A complete list
of the requested variables has been published elsewhere [8] and
is also included in Multimedia Appendix 1.

Study Clinical Measures
EHR data were systematically obtained from multiple clinical
sites and used to meaningfully capture clinical characteristics
(including viral suppression), initiation of antiretrovirals
(ARVs), and retention in care, which are part of the CDC’s
diagnosis-based HIV care continuum measures (Multimedia
Appendix 2) [10]. Two of the four CDC treatment cascade
measures—retention in care and viral suppression—were
assessed using routine EHR data. For the retention in care
measure, we used the CDC definition of an interval of >190
days (approximately 3 months) between laboratory visits for
CD4 or VL testing to indicate less-than-optimal laboratory visit
JMIR Form Res 2022 | vol. 6 | iss. 4 | e25483 | p. 2
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patterns. We were able to obtain laboratory visit dates and use
data from the subsequent year to determine whether the
participant was retained in care. Viral suppression was defined
as having a nondetectable baseline VL. Laboratories used by
individual study sites have varying lowest detectable limits for
VL; therefore, this study records undetectable VL as defined
by each study site. Additional measures calculated using EHR
data included ARV medication percentage and AIDS status.
Antiretroviral medication (%) was defined as the percentage of
patients with at least one recorded ARV therapy (ART)
prescription. The data in the EHR did not allow us to estimate
patients’ adherence to ARV because adherence is not
documented in the EHR and only issued prescriptions, not
prescription fills, are recorded. AIDS status was determined by
an absolute CD4 T-cell count of <200.

Feasibility of EHR Data Extraction Process by Study
Sites
Multiple EHR platforms are available for the computerized
entry of patient medical information. Although a close
examination of EHR platforms is important, information on the
types of EHR software was not collected because the intent of
the CM study was to examine the feasibility of standardized
extraction of clinical and cost data of relevance to CM data
across multiple EHR systems. Following interviews with study
coordinators about the consistency of EHR variable capture, 9
variables were deemed as primary and could be consistently
calculated. The following information was provided if available:
date of visit, age, sex, height, weight, race, ethnicity, VL, and
ICD-10 codes for other diagnoses. Data were requested as
comma-delimited files in Excel (Microsoft Corporation).
Because the sites have very different access to local technical
support for file extraction, the file structure was left to decisions
by the sites to ease the workload on the site staff. Data extraction
was supported by the provision of an example study data
dictionary for each site. This document shows how the variables
are optimally defined and delivered. However, the actual
extraction files differed for each of the 10 sites in terms of
design, organization, variable definition, and completeness.
Files had to contain the minimum primary variables, be
deidentified with a site-specific patient identifier, and a report
provided explaining the reason why any variables were missing.
CM study personnel received and approved a variable checklist
for each site before the data were approved for uploading. Upon
initial receipt of the 2016 data, the data were checked for
patterns of variable missingness, congruence with the data
request, and the presence of variables for linking relational data
by anonymous patient identifiers.

Data Management
Once the data extract was certified for a site, data were cleaned
and transformed into a common data model format. Most of the
data cleaning and construction of common data model files were
performed using SAS (version 9.4; SAS Institute Inc). Once
files for all sites were cleaned and variable values were
transformed to fit the common data model for the CM study,
we constructed a baseline demographics flat-file with one
observation per patient and a set of relational vertical files
organized by visit (laboratory test or prescription) date. We
https://formative.jmir.org/2022/4/e25483

XSL• FO
RenderX

Dark et al
constructed separate files for visits, laboratory values, ARV
medications, and other medications. The visit file contained all
CPT and ICD-10 diagnosis codes and formed the basis for the
development of a cost value for each encounter.

Data Analysis
Costing information was necessary to evaluate whether it was
possible to produce visit cost weights using CPT codes from
EHR data in lieu of extracting billing and administrative data,
which are often difficult to obtain from a clinic. The ability to
estimate cost is important for measuring variations in resource
use and efficiency in the process of care at clinical sites. These
estimated costs will be examined for validity using a time-driven
activity-based costing approach once more data are collected.
We used a standard costing approach to assign a cost value to
each encounter, because EHR data rarely contain cost data. Cost
data for individual sites are usually located in a Charge Master
file, which is updated as prices at the site change. The Charge
Master files are combined into billing costs for a visit using the
clinic accounting data system. Thus, EHR data do not contain
cost data per se but can be used to identify costs per event by
combining CPT codes with standard cost data. This approach
decreases the internal validity of cost estimates for an individual
site but greatly improves the validity of estimation of any
resource use and cost differences between sites and has greater
external validity of economic estimates made using the study
costs [11]. The CPT codes in each visit record were used to
assign a visit cost based on the median charge for the CPT code
published for all medical practices in the United States in 2016
[12].
An exploratory data analysis was conducted to understand the
breadth and specificity of the available data. Descriptive
statistics, including measures of central tendency, were
generated to identify outliers and to track data consistency for
future downloads. This study provides the first descriptive
analysis performed on the 2016 data as part of the development
of a common data model for the study. The analysis was
performed using SAS (version 9.4). Groups were compared
using chi-square tests for categorical variables and 2-talied t
tests (normally distributed) or Mann-Whitney U or Wilcoxon
tests (nonnormally distributed) for continuous variables.

Results
Feasibility of Variable Downloads by Study Sites
The parent SIU study was launched in December 2017 at 10
clinical sites, with 2016 EHR data due on January 31, 2017.
Site personnel often reported a lack of consistent access to
information technology (IT) and data management specialists
as the primary explanation for the delay in data submission.
Although the sites varied in the length of time to obtain and
prepare data (2-6 months), all sites successfully submitted data
to the designated data repository by May 2018. The primary
variables requested to monitor the cascade of care included the
date of visit, age, sex, height, weight, race, ethnicity, VL, and
ICD-10 codes for other diagnoses. In total, 70% (7/10) of the
sites provided data for the primary variables via the extraction
of electronic records from their EHR system. The remaining
JMIR Form Res 2022 | vol. 6 | iss. 4 | e25483 | p. 3
(page number not for citation purposes)

JMIR FORMATIVE RESEARCH
sites provided the primary variables using manual data
extraction.
The process of data cleaning and transforming the data into a
common data model format was an extremely labor-intensive
process that required >400 hours of expert programming and
data management work. More importantly, it required extensive
consultation between individuals with informatics programming
expertise and researchers with HIV-specific treatment data
experience. The extent of the work required to transform the
data into a common analyzable data model was unexpected.
Some of the most time-consuming tasks were needed because
the EHR systems for a site did not use clearly defined uniform
values for many of the variables. Definitions for some
demographic variables (sex, gender, race, and ethnicity) varied
within a site’s data download owing to the hand entry of
variables, and the use of upper and lower cases, codes, and
narrative descriptions. Visit variables that contained ICD-10
diagnosis codes and CPT codes were often problematic because
they were sometimes extracted as string variables, separated by
a mix of spaces and semicolons. Medication files were especially
labor-intensive because similar medications had different names,
spellings, abbreviations, and patterns of upper cases and
hyphens. Laboratory tests had different definitions of VL and
CD4 cell counts, and the names of other laboratory tests varied
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greatly and were sometimes not clearly identified. These
difficulties were resolved by querying sites for information and
by using site-specific detailed cleaning programs written for
this purpose. Laboratories have varying lowest detectable limits
for VL; therefore, this study records undetectable VL as defined
by each study site.

Baseline Participant Characteristics
A total of 1093 patients were enrolled in 2016 (Table 1). The
demographic variables had the lowest frequency of missing
values (4%-5%). ARV medication records were not available
for 17.75% (194/1093) of the patients. The VL was missing for
6.40% (70/1093) of the patients. This variable was
hand-extracted at the site if missing, indicating that some
patients did not have a VL record entered as structured data into
their EHR system. A CD4 cell count, an important measure of
immune status, was missing for approximately 28.81%
(315/1093) of cases. However, we did not require this variable
to be hand extracted, so it is possible that CD4 cell tests for
many patients may have been performed in an external
laboratory with results uploaded as a report. It may be important
to make CD4 cell count required by hand extraction when
electronic extraction is not possible, if we need to use this
variable to measure changes in immune status over time.

JMIR Form Res 2022 | vol. 6 | iss. 4 | e25483 | p. 4
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Table 1. Characteristics of the cascade monitoring study population at baseline (N=1093).
Characteristic

Patient value

Number of patients for whom 2016
data were missinga

Age (years), mean (SD)

20.8 (2.5)

41

Height (cm), mean (SD)

169.9 (10.9)

104

Weight (kg), mean (SD)

76.8 (18.5)

84

BMI (kg/m ), mean (SD)

26.6 (6.6)

106

Male sex, n (%)

730 (70.67)

60

2

Race, n (%)

50

Black

769 (73.73)

White

89 (8.53)

Hispanic

105 (10.07)

Other

80 (7.67)

Antiretroviral medication, n (%)

884 (98.3)

194

Patients with AIDS, n (%)

77 (9.9)

315

Baltimore, Maryland

94 (8.60)

N/Ab

Birmingham, Alabama

69 (6.31)

N/A

Brooklyn, New York

115 (10.52)

N/A

Los Angeles, California

85 (7.78)

N/A

Miami, Florida

54 (4.94)

N/A

Memphis, Tennessee

193 (17.66)

N/A

Philadelphia, Pennsylvania

78 (7.14)

N/A

San Diego, California

105 (9.61)

N/A

Tampa, Florida

219 (20.03)

N/A

Washington, District of Columbia

81 (7.41)

N/A

Mean total cost per visit (US $) across CPTc codes, mean (SD)

325 (376)

N/A

CD4 Laboratory results, mean (SD)

609.4 (316)

315

Viral load laboratory results, mean (SD)

25,608 (114,184)

70

Visits, mean (SD)

5.4 (4.6)

24

Patients with laboratory visits >190 days apart in 2016, n (%)

84 (8.15)

N/A

Patients in 2016 with no record in 2017, n (%)

202 (18.48)

N/A

Site reported sample size, n (%)

a

Missing 2016 data elements for race, age, sex, height, and weight were extracted from 2017, if available.

b

N/A: not applicable.

c

CPT: Current Procedural Terminology.

Patient Care Continuum Outcomes
Only 2 of the 4 CDC treatment cascade measures can be
assessed using routine EHR data. EHR data are not adequate
for monitoring HIV testing or linkage to care because the
denominator data are not available. However, the data work
well for measuring ART initiation and adequately for retention
in care. The criterion used to indicate less-than-optimal retention
visit patterns for CD4 or VL testing is detailed in the Methods
section. On the basis of this criterion, approximately 82.97%
(887/1069) of the patients met the minimum criteria for
https://formative.jmir.org/2022/4/e25483
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laboratory visit frequency. On average, our patient cohort had
5.4 (SD 4.6) laboratory visits per year in 2016, with a range of
1 to >150 visit records. All prescribed ARV and other
medications were requested for the study participants. A total
of 98.3% (884/899) of the patients from sites that were able to
extract medication records had at least one record of prescribed
ARV medication. This finding is in line with the Joint United
Nations Program on HIV proposed target that 90% of all people
with diagnosed HIV infection receive sustained ART by 2020
[13].
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We compared patients with undetectable baseline VL to those
with a VL value above the level of detection used by the VL
test in their center (Table 2). Minority race and ethnicity patients
were more likely to have detectable VL (P=.03) with 77.9%
(313/402) of patients with detectable VL being of Black or
African American race compared with 72.6% (355/489) of
patients being Black or African American with undetectable
VL. The findings showed poorer immune marker values for
patients with a detectable VL. A total of 45.6% (194/424) of
these patients had a mean VL of >10,000, and 29% (41/141)
had a CD4 cell count that classified them as having AIDS. In
addition, a small number of patients in the group with suppressed

VL at baseline (7/521, 1.3%) also had a CD4 cell count that
classified them as having AIDS.
The mean CD4 cell count was 619 (SD 310), indicating that
many of the 945 patients with CD4 cell count values had a
relatively good immune status. However, 5.7% (54/945) of
patients with available CD4 cell count values had a baseline
count of <200, which classified them as having AIDS by the
CDC. The VL burden was reported to be undetectable in 55.1%
(521/945) of the patients. However, a total of 20.5% (194/945)
of all patients with a VL record had a baseline (first VL available
in 2016) VL of >10,000 copies/mL.

Table 2. Characteristics of patients with undetectable and detectable VLa at baseline (N=945).b
Characteristics

Patients with undetectable baseline VL

Patients with detectable baseline VL

P value

Patients in the study, n (%)

521 (55.1)

424 (44.9)

.002

Age (years), mean (SD)

20.8 (2.6)

20.8 (2.5)

.71

Male sex, n (%)

328 (62.9)

296 (69.8)

.06

Race and ethnicity, n (%)
Black

355 (68.1)

313 (73.8)

White

46 (8.8)

20 (4.7)

Hispanic

26 (5.0)

28 (6.6)

Other

62 (11.9)

41 (9.7)

N/Ac

194 (45.7)

—d

Log10 VL if VL was detectable, mean (SD) N/A

3.6 (1.2)

—

CD4 cell count, mean (SD)

707 (274)

512 (321)

<.001

CD4 count <200 or with AIDS, n (%)

7 (1.3)

47 (11.1)

<.001

VL >10,000, n (%)

a

.03

VL: viral load.

b

A total of 148 patients had no baseline VL measures.

c

N/A: not applicable.

d

Statistical testing was not performed.

Discussion
Principal Findings
In preparation for the study, it became clear that some sites that
were considered for inclusion were unable to provide specific
variables. Therefore, the study team identified 9 mandatory
variables for which information must be provided for a site to
remain in the study. These mandatory variables (needed to
monitor the treatment cascade) included the following: (1) VL,
(2) date of visit, (3) age, (4) weight, (5) height, (6) ICD-10 and
CPT codes, (7) sex, (8) race, and (9) ethnicity. For the most
part, the sites were able to provide information regarding the
required data. The use of EHR data is effective in assessing the
patterns of completed appointments. However, in most cases,
these data are insufficient for identifying patterns of missed
appointments because such misses are not captured in the EHR
system. Direct electronic download may not be possible in all
situations; however, our data management team was able to
work with the sites to develop a successful plan for data
abstraction. Sites with good access to data management
resources can work more efficiently for CM purposes. However,
https://formative.jmir.org/2022/4/e25483
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we do not know the IT resources of the study sites. Many clinic
site personnel shared with the study investigators that they were
not sure who to contact for help or how much help they could
expect from their IT service group. Clinical staff members at
many sites have little day-to-day contact with IT data specialists.
This is an important issue that should be part of the selection
process when looking for site partners for clinical studies that
plan to use EHR data. Study planners should determine the
feasibility of additional funding for organizations in need of
additional IT or data management resources because these needs
are not always obvious at the planning stage.
A number of barriers to EHR use and lessons learned as part of
the CM study have come to light. First, the required variables
that are visible to clinicians on the EHR user interface may not
be readily available for electronic download. A number of
important variables are part of the narrative text or are simply
not recorded as structured data. VL, height, and weight are
examples of information contained within clinic notes or PDF
files of the results of tests performed off-site by a vendor and
only available as scanned reports. An HIV surveillance study
found that differences in estimated care engagement and viral
JMIR Form Res 2022 | vol. 6 | iss. 4 | e25483 | p. 6
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suppression between data sources revealed incomplete
laboratory reporting and that patients received care from
multiple providers [14]. Such findings highlight the potential
unavailability of information pertinent to treatment CM and
make monitoring dashboard construction infeasible. Some data
require hand extraction, and sites cannot easily find the data.
Patient height is often not recorded, which makes it difficult to
define important measures, such as overweight, obesity, or BMI.
Laboratory data extracts may lack important definitions of
normal. Undetectable VL is especially difficult to standardize
in a common data model because the laboratory definition varies
according to the type of test used. Some important characteristics
of the youth population infected with HIV were not recorded.
Sexual partner preference or sexual orientation is not routinely
documented in clinics. Sex is sometimes provided as gender
and sometimes as biological sex. Missing data are common,
and there are few explanations for missing data, but our
comparison of data from 2016 and 2017 indicates that variables
with missing values in 1 year tend to be within a normal range
if present subsequently, so we suspect that they are most likely
missing at random. This means that current statistical approaches
for dealing with missing data may not be good choices for use
in EHR data studies. In addition, there may be a discrepancy
between the information provided during a consultation and
that reported in the EHR [15], and vital information regarding
participation is not captured or readily accessible. Much
important information in an EHR for youth infected with HIV
is located in unstructured data such as physician, nurse, or social
worker notes. Neither data formatting nor hand cleaning will
solve this lack of structured data. What may be needed is text
recognition software and natural language processing
approaches. However, these methods are costly and pose
problems with regard to deidentifying data.
The study findings indicate that a substantial disease burden is
present in this very young population infected with HIV.
However, EHR data can be systematically obtained from
multiple clinical sites and used to meaningfully capture the
CDC’s continuum of care measures. In addition, this study used
standard cost values attached to CPT codes to estimate the cost
per visit. This approach delineates the differences in prices
between sites and proves the internal and external validity of
cost estimates. To the best of our knowledge, this is the first
EHR study to use this approach.
As previously stated, to fully benefit from advances in HIV
treatment, youth must actively engage in each step of the
treatment cascade. Although EHRs sufficiently capture
pathology and many other aspects of health, obtaining
meaningful indicators of health and treatment outcomes
regarding patient activity measures of the care continuum (eg,
keeping appointments and taking ART medications as
prescribed) proved more difficult. Among other
recommendations, Newman-Griffis et al [16] suggested specific
actions to improve the capture and analysis of activity and
participation information throughout the continuum of care,
including (1) making activity and participation annotation
standards and data sets available to the broader research
community and (2) establishing standards for how and when to
document activity and participation status during clinical
https://formative.jmir.org/2022/4/e25483
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encounters. A data-driven approach leveraging current
techniques in health informatics to extract information about
function, particularly activity and participation, is needed
[16,17].

Conclusions
The work performed as part of the CM study has greatly
advanced our understanding of the strengths and weaknesses
of using EHR data to monitor the treatment cascade in youth
infected with HIV. The analysis of the data from the first year
of the study indicates that EHR data can be extracted from
diverse sites and converted into analyzable data sets capable of
monitoring important variables in the HIV treatment cascade.
However, the success of any such effort will depend entirely
on a solid collaboration between investigators and staff at the
sites and the study team responsible for the cleaning and
standardization of the data. The support of clinical investigators
at the site has been essential for the success of the project, and
the study would not have been possible without the extraordinary
level of commitment and willingness to overcome obstacles
exhibited by the clinical site staff. The work effort was much
greater than expected for the CM study team. However, it
appears that the careful programming work performed to
transform the 2016 data is paying off because the 2017 data
have been downloaded, and early cleaning efforts indicate that
much of the work conducted for 2016 is usable for the 2017
data download. This is encouraging and indicates that up-front
work on a standard data model pays off in terms of efficiency
in subsequent years. This study provides pilot data on the use
of EHRs to determine who and when youth living with
HIV/AIDS disengage from the cascade and a broad,
nonintrusive, and efficient way of assessing whether SIU
interventions improve cascade outcomes. We conclude that
although the use of EHR data for treatment CM for youth with
HIV is labor-intensive and not ideal for some measures, it works
for much of what we need to know about monitoring retention
in care. Thus, it has the potential to become an essential tool
for measuring the achievement of the goal of improving access
to quality care for youth infected with HIV in the United States.

Future Directions
The longitudinal design of this study will allow for the
calculation of cascade measures (ART prescription, viral
suppression, and retention in care) throughout the study time
fame of 2016 to 2021. In addition, advanced analytic procedures
will be used to model care retention based on both
patient-related and clinical characteristics, resulting in the
creation of patient phenotypes for youth living with HIV/AIDS.
Creation of the phenotypes will facilitate the identification of
relevant predictors associated with dropout at any stage of the
cascade and will be used to estimate the cost per quality-adjusted
life year expected from cascade outcomes. As part of the
identification of the larger cost-of-illness burden of cascade
lapses for youth living with HIV/AIDS, we will use the EHR
phenotypes and archival data from Medicaid or privately insured
populations to model the extent of cascade interruptions present
in other practice settings. The data will be combined with the
individual cost weights to estimate the variations in the
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economic burden that cascade disruptions for youth living with
HIV/AIDS place on US communities.
With the development of phenotypes, we will be able to extend
our study findings to identify lapses in the treatment cascade
for youth living with HIV/AIDS using large national databases.

Dark et al
This process will permit the enumeration of these patient
phenotypes nationwide and the description of the related annual
economic costs of care. This will enable us to identify
meaningful variations between communities that can then serve
as the basis for targeted interventions.
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